Annexon, Inc. (ANNX): Shareholders' Equity
$211.65M
As of 2025-12-31
$186.06M
As of 2026-06-30
-2.9%
3-year compound annual growth
-9.3%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $211.65M | -27.8% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $293.11M | +17.0% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $250.56M | +8.4% | 2025-03-03, Balance as of period end |
| 2022-12-31 | $231.19M | -0.3% | 2024-03-26, Balance as of period end |
| 2021-12-31 | $231.91M | -32.6% | 2023-03-06, Balance as of period end |
| 2020-12-31 | $344.28M | n/m | 2022-03-01, Balance as of period end |
| 2019-12-31 | -$100.45M | n/a | 2021-03-25, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Annexon, Inc. (ANNX) | 2025-12-31 | $211.65M | -27.8% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $245.15M | +75.7% |
| Contineum Therapeutics, Inc. (CTNM) | 2025-12-31 | $260.99M | +31.8% |
| Altimmune, Inc. (ALT) | 2025-12-31 | $224.89M | +82.1% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $89.83M | +47.9% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $64.72M | -49.8% |
| Tyra Biosciences, Inc. (TYRA) | 2025-12-31 | $259.18M | -24.5% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $213.99M | -11.2% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $154.66M | +289.9% |
Compare ANNX, TNXP, CTNM, ALT side by side · Screen every company in Pharmaceutical Preparations ↗